1. Home
  2. WPAC vs TLSA Comparison

WPAC vs TLSA Comparison

Compare WPAC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WPAC

White Pearl Acquisition Corp. Class A Ordinary Shares

N/A

Current Price

$9.98

Market Cap

156.8M

Sector

Finance

ML Signal

N/A

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$0.98

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WPAC
TLSA
Founded
2025
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.8M
155.3M
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
WPAC
TLSA
Price
$9.98
$0.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
258.9K
Earning Date
N/A
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.82
$0.87
52 Week High
$11.89
$2.60

Technical Indicators

Market Signals
Indicator
WPAC
TLSA
Relative Strength Index (RSI) 45.30 40.47
Support Level $9.96 N/A
Resistance Level $10.11 $1.45
Average True Range (ATR) 0.00 0.12
MACD -0.01 -0.02
Stochastic Oscillator 0.00 17.74

Price Performance

Historical Comparison
WPAC
TLSA

About WPAC White Pearl Acquisition Corp. Class A Ordinary Shares

White Pearl Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: